{
  "id": 5544075,
  "title": "Immuron To Launch PROIBS In U.S. After Australia Debut; Pre-market Shares Up",
  "url": "https://urgent.news/2026/09/04/immuron-to-launch-proibs-in-u-s-after-australia-debut-pre-market",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-04T11:02:20.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/immuron-launch-proibs-us-after-australia-debut-pre-market-shares"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Australian biopharmaceutical company Immuron Ltd. (IMC.AX, IMRN), announced on Friday that it has signed an exclusive distribution deal with Sweden's Calmino group AB to launch its digestive health product PROIBS in the United States, following its rollout in Australi",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}